Mapping of human cerebral sigma1 receptors using positron emission tomography and [11C]SA4503

The objective of this study was to establish the kinetic analysis for mapping sigma(1) receptors (sigma1Rs) in the human brain by positron emission tomography (PET) with [(11)C]SA4503. The sigma1Rs are considered to be involved in various neurological and psychiatric diseases. [(11)C]SA4503 is a recently developed radioligand with high and selective affinity for sigma1Rs, and we have first applied it to clinical studies. Nine healthy male subjects each underwent a dynamic 90-min PET scan after injection of [(11)C]SA4503. In addition to the baseline measurement, three of the nine subjects underwent a second [(11)C]SA4503-PET after partial blockade of sigma1Rs by oral administration of haloperidol, a sigma receptor antagonist. Full kinetic analysis using two times nonlinear estimations was applied for fitting a two-tissue three-compartment model to determine the binding potential (BP) and total distribution volume (tDV) of [(11)C]SA4503. Graphical analysis with a Logan plot was also applied for estimations of tDV. The regional distribution patterns of BP and tDV in 11 regions were compatible with those of previously reported sigma1Rs in vitro. The reduced binding sites of sigma1Rs by haloperidol were appropriately evaluated. The tDVs derived from the two methods matched each other well. The Logan plot offered images of the tDV, which reflected sigma1R densities, and the tDV in the images decreased after haloperidol loading. Moreover, comparison of BPs calculated with and without metabolite correction for plasma input function indicated that the metabolite correction could be omitted. We concluded that this method enables the quantitative analysis of sigma1Rs in the human brain.

[1]  M. Raichle,et al.  Cerebral Blood Volume Measured with Inhaled C15O and Positron Emission Tomography , 1987, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[2]  Kunihiro Chihara,et al.  A feasibility study of [11C]SA4503-PET for evaluating sigma1 receptor occupancy by neuroleptics: The binding of haloperidol to sigma1 and dopamine D2-like receptors , 2006, Annals of nuclear medicine.

[3]  Thomas F. Coleman,et al.  Optimization Toolbox User's Guide , 1998 .

[4]  Michio Toru,et al.  Sigma receptors in schizophrenic cerebral cortices , 1992, Neurochemical Research.

[5]  J. Hedreen,et al.  Sigma receptors in post-mortem human brains. , 1988, The Journal of pharmacology and experimental therapeutics.

[6]  Kiichi Ishiwata,et al.  Sigma receptor ligands: possible application as therapeutic drugs and as radiopharmaceuticals. , 2006, Current pharmaceutical design.

[7]  Hideo Tsukada,et al.  An increase of sigma1 receptors in the aged monkey brain , 2003, Neurobiology of Aging.

[8]  Junien Jl,et al.  Drugs acting on sigma and phencyclidine receptors: a review of their nature, function, and possible therapeutic importance. , 1989 .

[9]  Kjell Erlandsson,et al.  [123I]TPCNE—A novel SPET tracer for the sigma‐1 receptor: First human studies and in vivo haloperidol challenge , 2006, Synapse.

[10]  Robert H Mach,et al.  N‐[18F]4′‐fluorobenzylpiperidin‐4yl‐(2‐fluorophenyl) acetamide ([18F]FBFPA): A potential fluorine‐18 labeled PET radiotracer for imaging sigma‐1 receptors in the CNS , 2005, Synapse.

[11]  David J. Schlyer,et al.  Graphical Analysis of Reversible Radioligand Binding from Time—Activity Measurements Applied to [N-11C-Methyl]-(−)-Cocaine PET Studies in Human Subjects , 1990, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[12]  M Slifstein,et al.  Effects of statistical noise on graphic analysis of PET neuroreceptor studies. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[13]  Steven G. Potkin,et al.  Decrease in σ but no increase in striatal dopamine D4 sites in schizophrenic brains , 1996 .

[14]  W C Eckelman,et al.  Kinetic Analysis of the 5-HT2A Ligand [11C]MDL 100,907 , 2000, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  William H Hoffman,et al.  Regulation of female fertility and identification of future contraceptive targets. , 2006, Current pharmaceutical design.

[16]  Keiichi Oda,et al.  Tumor Imaging with 2 -Receptor Ligands, 18 F- FE-SA5845 and 11 C-SA4503: A Feasibility Study , 2004 .

[17]  M. Senda,et al.  Preclinical evaluation of [11C]SA4503: radiation dosimetry,in vivo selectivity and PET imaging of sigma1 receptors in the cat brain , 2000, Annals of nuclear medicine.

[18]  Kazunori Kawamura,et al.  Tumor imaging with 2 sigma-receptor ligands, F-18-FE-SA5845 and C-11-SA4503 : A feasibility study , 2004 .

[19]  Teruo Hayashi,et al.  Understanding the molecular mechanism of sigma-1 receptors: towards a hypothesis that sigma-1 receptors are intracellular amplifiers for signal transduction. , 2003, Current medicinal chemistry.

[20]  Hideo Tsukada,et al.  Mapping of CNS sigma1 receptors in the conscious monkey: Preliminary PET study with [11C]SA4503 , 2001, Synapse.

[21]  T Sasaki,et al.  Function of sigma1 receptors in Parkinson's disease , 2005, Acta neurologica Scandinavica.

[22]  D. Mash,et al.  Sigma receptors are associated with cortical limbic areas in the primate brain , 1992, Synapse.

[23]  T. Brubaker,et al.  Nonlinear Parameter Estimation , 1979 .

[24]  Yoichi Kawashima,et al.  Binding properties of SA4503, a novel and selective σ1 receptor agonist , 1996 .

[25]  D E Kuhl,et al.  Compartmental Analysis of [11C]Flumazenil Kinetics for the Estimation of Ligand Transport Rate and Receptor Distribution Using Positron Emission Tomography , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[26]  Yuichi Kimura,et al.  Quantitative analysis of adenosine A1 receptors in human brain using positron emission tomography and [1-methyl-11C]8-dicyclopropylmethyl-1-methyl-3-propylxanthine. , 2004, Nuclear medicine and biology.

[27]  H Orihara,et al.  Performance evaluation of a large axial field-of-view PET scanner: SET-2400W , 1997, Annals of nuclear medicine.

[28]  K. Jansen,et al.  Loss of sigma binding sites in the CA1 area of the anterior hippocampus in Alzheimer's disease correlates with CA1 pyramidal cell loss , 1993, Brain Research.

[29]  Rikki N. Waterhouse,et al.  Halogenated 4-(phenoxymethyl)piperidines as potential radiolabeled probes for σ-1 receptors : In vivo evaluation of [123I]-1-(iodopropen-2-yl)-4-[(4-cyanophenoxy)methyl]piperidine , 1997 .

[30]  Su Tp,et al.  Delineating biochemical and functional properties of sigma receptors: emerging concepts. , 1993 .

[31]  Edythe D. London,et al.  Selective loss of cerebral cortical Sigma, but not PCP binding sites in schizophrenia , 1991, Biological Psychiatry.

[32]  Kiichi Ishiwata,et al.  In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors , 2000 .

[33]  Kiyoshi Matsuno,et al.  SA4503: A Novel Sigma1 Receptor Agonist , 1998 .

[34]  Robert B. Innis,et al.  Strategies to Improve Neuroreceptor Parameter Estimation by Linear Regression Analysis , 2002, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[35]  Kiichi Ishiwata,et al.  Sigma1 and dopamine D2 receptor occupancy in the mouse brain after a single administration of haloperidol and two dopamine D2-like receptor ligands. , 2003, Nuclear medicine and biology.

[36]  John A. Nelder,et al.  A Simplex Method for Function Minimization , 1965, Comput. J..

[37]  B. Ardekani,et al.  A Fully Automatic Multimodality Image Registration Algorithm , 1995, Journal of computer assisted tomography.

[38]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.